IP Library Patent Application 12754122
Patent Application
App. No. 12/754,122

Intraocular Lens Injector with Hydrophilic Coating

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/754,122
Filed
Apr 5, 2010
Art Unit
3731
USPC
623/6.12
Abstract

An IOL injector that includes one or more polymeric portions that include a hydrophilic coating component that is effective to facilitate the passage of the IOL through the injector, particularly an injector tip. The IOL injector is prepared by a process that includes irradiating at least a portion of a polymeric, IOL injector with UV light in an environment comprising oxygen to provide a positive percent change in the atomic oxygen content of the polymer material at the surface as determined by X-ray Photoelectron Spectroscopy (XPS). A portion or the entire irradiated portion is then contacted with a solution comprising a hydrophilic coating component. The hydrophilic coating component is selected from a hydrophilic polymer, a hydrophilic copolymer or any one mixture thereof to provide a solution coated portion. The solution coated portion is then heated at a temperature to provide portions of the IOL injector with a shelf-stable, lubricious hydrophilic coating to facilitate delivery of an IOL from the injector.

Claims (21)

1 . An intraocular lens injector prepared by a process comprising:

irradiating at least a portion of a polymeric, intraocular lens injector with UV light in an environment comprising oxygen to provide a positive percent change in the atomic oxygen content of the polymer material at the surface as determined by X-ray photoelectron spectroscopy;

contacting at least a portion of the irradiated portion with a solution comprising a hydrophilic polymer, a hydrophilic copolymer or any one mixture thereof to provide a solution coated portion; and

heating the solution coated portion to provide the lens injector with a shelf-stable, lubricious coating to facilitate delivery of an intraocular lens from the injector with minimal damage to the lens and with little or no transfer of the lubricious coating to a surface of the lens.

2 . The intraocular lens injector of claim 1 further comprising:

contacting at least a portion of the irradiated portion with a solution comprising a crosslinkable polymer and initiating the crosslinking with light or heat prior to contacting at least a portion of the irradiated portion with the solution comprising a hydrophilic polymer, a hydrophilic copolymer or any one mixture thereof.

3 . The intraocular lens injector of claim 1 wherein the hydrophilic polymer is selected from the group consisting of polyacrylic acid, polymethacrylic acid, polyvinylacetate, polyacrylamide and polyvinylpyrrolidone.

4 . The intraocular lens injector of claim 1 wherein the hydrophilic copolymer is selected from poly(PVP-VA), poly(PVP-AA) or poly(PVP-DMA).

5 . The intraocular lens injector of claim 1 wherein the hydrophilic polymer is a polyether polyurethane.

6 . The intraocular lens injector of claim 1 wherein the UV light is UV-C light.

7 . The intraocular lens injector of claim 1 wherein the hydrophilic copolymer is poly(PVP-VA) with a PVP:VA ratio of 30:70 to 80:20.

8 . The intraocular lens injector of claim 1 wherein the portion of a polymeric, intraocular lens injector that is irradiated with UV light comprises polypropylene, and the atomic oxygen content of the polymer material at the surface of said irradiated portion prior to contacting said portion with a solution comprising a hydrophilic polymer, a hydrophilic copolymer or any one mixture thereof, is from 5 at. % to 20 at. % as determined by X-ray photoelectron spectroscopy.

9 . The intraocular lens injector of claim 1 wherein the shelf-stable, lubricious coating exhibits greater shelf-stability than a similar lubricious coating applied without irradiation with the UV light.

10 . An intraocular lens injector tip prepared by a process comprising:

irradiating an intraocular lens injector tip comprising polypropylene with UV-C light in an environment comprising oxygen to provide a surface, atomic oxygen content of the injector tip from 5 at. % to 20 at. % as determined by X-ray photoelectron spectroscopy;

contacting the irradiated injector tip with a solution comprising a hydrophilic polymer, a hydrophilic copolymer or any one mixture thereof to provide a solution coated portion; and

heating the solution coated injector tip at a temperature from 35° C. to 110° C. to provide the injector tip with a shelf-stable, lubricious coating to facilitate delivery of an intraocular lens from an intraocular lens injector with minimal damage to the lens and with little or no transfer of the lubricious coating to a surface of the lens.

11 . The injector tip of claim 10 wherein the hydrophilic polymer is selected from the group consisting of polyacrylic acid, polymethacrylic acid, polyvinylacetate, polyacrylamide, polyvinylpyrrolidone and polyether polyurethane.

12 . The injector tip of claim 10 wherein the hydrophilic copolymer is selected from poly(PVP-VA), poly(PVP-AA) or poly(PVP-DMA).

13 . The injector tip of claim 10 wherein the hydrophilic copolymer is poly(PVP-VA) with a PVP:VA ratio of 30:70 to 80:20.

14 . The injector tip of claim 10 wherein the hydrophilic polymer is a polyether polyurethane.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2010
From: JANI, DHARMENDRA; CHITRE, KAUSTUBH S.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 024353/0137 →